Corrigendum: Bispecific NK-cell engager targeting BCMA elicits stronger antitumor effects and produces less proinflammatory cytokines than T-cell engager

Xinghui Xiao, Ying Cheng, Xiaodong Zheng, Yuhang Fang, Yanwen Zhang, Rui Sun, Zhigang Tian, Haoyu SunFrontiers in Immunology 2024 · DOI · OpenAlex

Introduction

This document serves as a formal corrigendum for the research article "Bispecific NK-cell engager targeting BCMA elicits stronger antitumor effects and produces less proinflammatory cytokines than T-cell engager," originally published in Frontiers in Immunology in 2023. While the primary function of this update is to correct administrative errors within the funding statement, it provides an opportunity to revisit the significant scientific contributions of the original study regarding safer cancer immunotherapies.

Addressing the "Cytokine Storm" in Immunotherapy

The original research tackled a critical challenge in modern oncology: the severe side effects associated with T-cell engagers. While bispecific antibodies that recruit T-cells to attack tumor cells are highly effective, they frequently trigger "cytokine release syndrome" (CRS). This systemic inflammatory response can be life-threatening for patients.

The study investigated whether Natural Killer (NK) cells could serve as a safer alternative effector mechanism. By developing a bispecific engager targeting the B-cell maturation antigen (BCMA)—a common target in multiple myeloma—the researchers aimed to maintain high antitumor potency while minimizing the risk of a cytokine storm.

The Nature of the Corrigendum

The correction specifically addresses the "Funding" section of the original publication. In the initial release, several grant numbers and funding sources were misidentified or omitted. Accurate funding attribution is essential for maintaining the transparency and integrity of the scientific record, ensuring that supporting institutions receive proper credit.

The authors explicitly state that these clerical corrections "do not change the scientific conclusions of the article in any way." This confirmation ensures that the comparative data and the resulting therapeutic implications remain robust and valid for the scientific community.

Key Scientific Insights Reaffirmed

The title of the study encapsulates the "aha moment" of the research: by utilizing NK-cells instead of T-cells as the primary "engine" for the immunotherapy, a more favorable therapeutic window is achieved.

1. Superior Antitumor Efficacy

The bispecific NK-cell engager demonstrated stronger antitumor effects compared to its T-cell engager counterpart. This suggests that NK-cell recruitment may offer a more potent pathway for eliminating BCMA-positive cancer cells in certain contexts.

2. Enhanced Safety Profile

Crucially, the NK-cell approach produced significantly lower levels of proinflammatory cytokines. This finding supports the hypothesis that NK-cell-based therapies could drastically reduce the incidence and severity of cytokine release syndrome, making powerful immunotherapies accessible to a broader range of patients.

Corrected Funding Acknowledgments

The updated funding statement now accurately reflects support from the following sources:

  • National Key R&D Program of China: Grants 2019YFA0508502/3 and 2018YFA0507403.
  • Natural Science Foundation of China: Grants 8222053 and 81972679.
  • Natural Science Foundation of Anhui Province: Grant 2008085MH252.

Conclusion

While administrative in nature, this corrigendum reaffirms the validity of a promising advancement in cancer treatment. The transition from T-cell to NK-cell engagers represents a strategic shift toward high-efficacy, low-toxicity immunotherapy, potentially overcoming one of the most significant hurdles in the clinical application of bispecific antibodies.

Summary updated

Abstract

[This corrects the article DOI: 10.3389/fimmu.2023.1113303.].
BibTeX
@inproceedings{xiao2024corrigendum,
  author = {Xinghui Xiao and Ying Cheng and Xiaodong Zheng and Yuhang Fang and Yanwen Zhang and Rui Sun and Zhigang Tian and Haoyu Sun},
  title = {{Corrigendum: Bispecific NK-cell engager targeting BCMA elicits stronger antitumor effects and produces less proinflammatory cytokines than T-cell engager}},
  booktitle = {Frontiers in Immunology},
  year = {2024},
  doi = {10.3389/fimmu.2024.1365027},
}
Figure